PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsRemifentanil
Remifentanil
Remifentanil, Ultiva (remifentanil) is a small molecule pharmaceutical. Remifentanil was first approved as Ultiva on 1996-07-12. It is used to treat pain in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
signs and symptoms pathological conditionsD013568
psychological phenomenaD011579
musculoskeletal and neural physiological phenomenaD055687
Trade Name
FDA
EMA
Remifentanil, Ultiva
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Remifentanil hydrochloride
Tradename
Company
Number
Date
Products
ULTIVAMylanN-020630 RX1996-07-12
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
remifentanil hydrochlorideANDA2025-02-13
remifentanil hydrochloride remifentanil hydrochlorideANDA2020-10-16
ultivaNew Drug Application2023-12-21
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
painEFO_0003843D010146R52
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N01: Anesthetics
— N01A: Anesthetics, general
— N01AH: Opioid anesthetics
— N01AH06: Remifentanil
HCPCS
No data
Clinical
Clinical Trials
1064 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart diseasesD006331EFO_0003777I51.9———1—1
HyperglycemiaD006943—R73.9———1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRemifentanil
INNremifentanil
Description
Remifentanil is a piperidinecarboxylate ester that is methyl piperidine-4-carboxylate in which the hydrogen attached to the nitrogen is substituted by a 3-methoxy-3-oxopropyl group and the hydrogen at position 4 is substituted the nitrogen of N-propanoylaniline. It has a role as a mu-opioid receptor agonist, an opioid analgesic, an intravenous anaesthetic and a sedative. It is an anilide, a piperidinecarboxylate ester, a monocarboxylic acid amide and an alpha-amino acid ester.
Classification
Small molecule
Drug classnarcotic analgesics (fentanyl derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1
Identifiers
PDB—
CAS-ID132875-61-7
RxCUI—
ChEMBL IDCHEMBL1005
ChEBI ID8802
PubChem CID60815
DrugBankDB00899
UNII IDP10582JYYK (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 20,621 documents
View more details
Safety
Black-box Warning
Black-box warning for: Remifentanil hydrochloride, Remifentanil hydrochloride remifentanil hydrochloride, Ultiva
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,980 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use